# A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years

> **NCT06562985** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 39 (actual)

## Conditions studied

- Acute Venous and Arterial Thrombotic and Thromboembolic Events
- Healthy Volunteers

## Interventions

- **DRUG:** BAY3018250 Dose 1
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** BAY3018250 Dose 2 infusion
- **DRUG:** BAY3018250 Dose 2 injection

## Key facts

- **NCT ID:** NCT06562985
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-18
- **Primary completion:** 2025-01-06
- **Final completion:** 2025-01-06
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06562985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06562985, "A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06562985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*